GlassScriptPhysician profile
Lisa Biswas
NPI 1881182087
$8,077.00
in general payments reported to CMS, 2019-2025
25 companies · $4,073 in 2025
The $4,073 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $1,087 · 2023: $776 · 2024: $2,020 · 2025: $4,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,384 · Consulting Fee: $1,446 · Travel and Lodging: $39.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,383.67 |
| Consulting Fee | $1,446.00 |
| Travel and Lodging | $39.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,753.81 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,334.21 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,267.70 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Pharmaceuticals, INC. | $1,114.54 | 2022-2024 | Dupixent |
| Glaxosmithkline, LLC. | $465.64 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $307.71 | 2023-2025 | Cuvitru, Takhzyro, Eohilia |
| Grifols USA, LLC | $266.64 | 2024-2025 | Xembify |
| Pharming Healthcare, INC. | $222.98 | 2023-2025 | Joenja, Ruconest |
| Pfizer INC. | $189.05 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $187.02 | 2023-2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $180.72 | 2025 | Neffy |
| Csl Behring | $156.11 | 2024-2025 | Hizentra, Haegarda |
| Novartis Pharmaceuticals Corporation | $103.30 | 2024-2025 | |
| Optinose US, INC. | $98.77 | 2025 | |
| Kaleo, INC. | $63.70 | 2023-2024 | Auvi-Q |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $62.40 | 2025 | Tezspire |
| Hikma Pharmaceuticals USA | $55.04 | 2024-2025 | Ryaltris |
| Azurity Pharmaceuticals, INC. | $51.59 | 2025 | Alvesco |
| Alk-Abello, INC | $50.00 | 2023 | Odactra, Ragwitek, Grastek |
| Incyte Corporation | $48.03 | 2024 | Opzelura |
| Genentech USA, INC. | $23.41 | 2024 | Xolair |
| Galderma Laboratories, L.P. | $22.63 | 2025 | Nemluvio |
| Organon LLC | $20.24 | 2025 | Vtama |
| Aytu Biopharma, INC. | $17.32 | 2025 | |
| Lilly USA, LLC | $14.44 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Biswas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.